Top Speed on MSN1d
An Alternating Current Battery Pack Is Being Developed By PorscheBatteries, whether they’re small enough to power your smartwatch or big enough to run an all-electric pickup truck provide ...
Data from the SAPPHIRE study formed the basis of Scholar Rock's U.S. Food and Drug Administration request to approve ...
Dispatches for Honda's latest electric scooters, Activa e: and QC1, have commenced. Read the story to find out how much you ...
QRL-101 is designed to open Kv7.2/7.3 ion channels, which work as gates for potassium in nerve cells and help control their ...
A new report states that Austria-based contract manufacturer Magna Steyr is on the cusp of securing two new customers ...
Novartis has reported positive efficacy and safety outcomes from its Phase III clinical programme for OAV101 IT (onasemnogene ...
After bringing Zolgensma to market in 2019 as the first gene therapy for spinal muscular atrophy, Novartis is back with an intrathecal formulation intended for older patients.
Novartis' OAV101 IT gene therapy showed positive results in Phase 3 trials for SMA, with data supporting its potential as a ...
Novartis (NVS) announced positive safety and efficacy results from the Phase III program for investigational intrathecal onasemnogene ...
A pair of clinical data sets gives Novartis confidence in a new formulation of the company’s gene therapy Zolgensma for the ...
The hottest line in hockey since the Four Nations break has been Nick Suzuki's trio. It's why the Canadiens are fighting for a playoff spot. Brian Wilde has more.
August 15, 2025, is the FDA PDUFA goal date for TNX-102 SL for the management of fibromyalgia; If approved, TNX-102 SL would become the first new ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback